References in periodicals archive ?
2 Market Barriers 31 6 Critical Care Market to 2019 - Antithrombin Concentrate Market 32 6.
Protein C, protein S, and antithrombin reagent sets purchased from Diagnostica Stago all exceeded the manufacturer's precision claims with CVs <4%, except for the protein S intrarun CV on the abnormal control, which was 9%.
16) Protein S deficiency confers the highest relative risk, 10 (17), followed by Factor V Leiden (18) and protein C deficiency (19) at 7, antithrombin (20), 5, and the prothombin mutation, (13) with a ratio of 2.
Simon Lowry, Vice President of Medical Affairs at rEVO Biologics, "This study continues to underscore the important role of ATryn in the management of pregnant patients with hereditary antithrombin deficiency.
Antithrombin (Recombinant) is the first and only recombinant antithrombin concentrate, and is currently the fastest-growing antithrombin product with market share that has tripled in the last 12 months.
About 1 in 5,000 people don't produce enough antithrombin protein, according to
To mimic real clinical laboratory practice as much as possible, we used only lyophilized plasma from healthy volunteers or patients with antithrombin activity in the range of 400-1200 units/L for distribution within the surveys of the ECAT Foundation.
3) Heparin interference with the coagulation process is achieved by attaching to thrombin and antithrombin, by attaching to antithrombin alone, or by inhibiting platelets.
Because heparin cannot bind directly to thrombin, it must bind to another substance, antithrombin III, which in turn inhibits thrombin.
rEVO Biologics announced today that hereditary antithrombin (AT) deficiency, and the use of the company's lead product ATryn Antithrombin (Recombinant), in the successful treatment of a pregnant patient with hereditary AT deficiency to prevent thromboembolic events (blood clots) is the focus of a TV segment on Behind the Mystery: Rare and Genetic Diseases, the ground breaking series on The Balancing Act[TM], America's premier morning show that airs weekday mornings on Lifetime Television.
Annualized market data for the critical care market that includes markets for factor XIII concentrate, fibrinogen concentrate, antithrombin, prothrombin complex concentrate and albumin from 2002 to 2010, with forecasts to 2017
GTC, which already sells ATryn in Europe, is seeking approval to sell it in the United States as a treatment for hereditary antithrombin deficiency in patients undergoing surgery or childbirth.